Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.59 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22750481 | 0.94 | ADORA3 (0.55) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750584 | 0.92 | ADORA3 (0.62) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750550 | 0.91 | ADORA3 (0.52) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750478 | 0.90 | ADORA3 (0.51) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750608 | 0.90 | ADORA3 (0.54) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750588 | 0.89 | ADORA3 (0.56) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750488 | 0.87 | ADORA3 (0.57) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750497 | 0.87 | ADORA3 (0.48) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750582 | 0.86 | ADORA3 (0.50) | ADORA3ADORA1TMIGD3ADORA2BADORA2A | |
| SCHEMBL22750572 | 0.85 | ADORA3 (0.62) | ADORA3ADORA1TMIGD3ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020247546-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2020-12-10 | — | — | WO | disclosed |